May 23, 2025

New Inhaled Treprostinil Option Approved

Yutrepia represents an additional therapeutic option within the prostacyclin class for the management of PAH and PH-ILD.

Conexiant

May 22, 2025

Voices on the Go: Top Podcasts for Physicians

Physicians are tuning to podcasts that combine clinical insight, career development, and storytelling.

Conexiant

May 22, 2025

Extensive-Stage SCLC: Lurbinectedin and Atezolizumab

Results from the global phase III IMforte trial found that maintenance therapy with a combination of the alkylating agent lurbinectedin and the PD-L1 inhibitor atezolizumab improved survival in some p...

The ASCO Post

May 21, 2025

Medical Oddities: Fingernail Selfies Spot Anemia

Tea, tech, TikTok & toxins: surprising health twists hiding in phones, roads, and skin care.

Conexiant

May 19, 2025

Sleep Pattern Disruption Tied to Psych Symptoms

Blunted slow-wave sleep in 22q11.2 deletion syndrome was linked to increased daytime sleepiness and behavioral difficulties, including attention problems and negative psychotic symptoms.

Conexiant

May 19, 2025

Recent Advances in Treating Diffuse Large B-Cell Lymphoma

The disease we now call diffuse large B-cell lymphoma (DLBCL) has gone by the names of reticulum cell sarcoma, diffuse histiocytic lymphoma, and diffuse large cell lymphoma, and included both lymphoma...

The ASCO Post

May 16, 2025

Delandistrogene Moxeparvovec: Efficacy Evidence Questioned

The AAN Guidelines Subcommittee review finds delandistrogene moxeparvovec for DMD failed to meet primary functional outcomes despite FDA approval.

Conexiant

May 15, 2025

FDA Approves First Oral Therapy for Pheochromocytoma and Paraganglioma

The FDA has approved a HIF-2α inhibitor for adult and pediatric patients aged 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma and paraganglioma (PPGL). 

The ASCO Post

May 15, 2025

Afatinib vs Chemotherapy in NSCLC With Uncommon Activating EGFR Mutations

In an interim analysis of a Japanese trial (ACHILLES/TORG1834) reported in the Journal of Clinical Oncology, Miura et al evaluated whether afatinib prolonged progression-free survival vs platinum-base...

The ASCO Post